Edit |   |
Antigenic Specificity | TEK (TIE2) (C-term), 758-789 |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | human (predicted reactivity: bovine) |
Isotype | n/a |
Format | purified |
Size | 0.08 mL, 0.4 mL |
Concentration | vial concentration: 1.86 |
Applications | ELISA (EIA), Immunohistochemistry (IHC), Western Blot (WB) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | This TEK (TIE2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 758-789 amino acids from the C-terminal region of human TEK (TIE2). The TEK receptor tyrosine kinase is expressed almost exclusively in endothelial cells in mice, rats, and humans. This receptor possesses a unique extracellular domain containing 2 immunoglobulin-like loops separated by 3 epidermal growth factor-like repeats that are connected to 3 fibronectin type III-like repeats. The ligand for the receptor is angiopoietin-1. Defects in TEK are associated with inherited venous malformations; the TEK signaling pathway appears to be critical for endothelial cell-smooth muscle cell communication in venous morphogenesis. TEK is closely |
Immunogen | n/a |
Other Names | [Angiopoietin-1 receptor; Endothelial tyrosine kinase; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; hTIE2; p140 TEK; CD202b; TEK; TIE2; VMCM; VMCM1] |
Gene, Accession # | [TEK], Gene ID: 7010, NCBI: NP_000450.2, UniProt: Q02763 |
Catalog # | MBS9205459 |
Price | $165, $370 |
Order / More Info | TEK (TIE2) (C-term), 758-789 Antibody from MYBIOSOURCE INC. |
Product Specific References | Cascone, I., et al., Blood 102(7):2482-2490 (2003). DeBusk, L.M., et al., Arthritis Rheum. 48(9):2461-2471 (2003). Poncet, S., et al., Neuropathol Appl Neurobiol 29(4):361-369 (2003). Lee, H.J., et al., Biochem. Biophys. Res. Commun. 304(2):399-404 (2003). Sussman, L.K., et al., Cancer Biol. Ther. 2(3):255-256 (2003). |